Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies

NCT01026233 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01026233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
August 31, 2011
Enrollment
52 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin